Mar 29, 2024 15:19 JST

Source: Eisai

Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that “NouKNOW®”, Eisai’s self-check tool for brain health, was certified as a “ME-BYO BRAND” by Kanagawa prefecture.

About ”ME-BYO BRAND”

“ME-BYO BRAND”, is a certification granted to excellent products/services associated with pre-symptomatic diseases by Kanagawa Prefectural Government in an effort to raise awareness toward pre-symptomatic diseases and promote commercialization of endorsed products/services. It recognizes products/services that contribute to the visualization of pre-symptomatic diseases in the areas of lifestyle, life functions, mental health/stress, and cognitive function, which lead to changes in the awareness and behavior of Kanagawa prefecture residents.

“NouKNOW”, a Self-Check Tool for Brain Health

NouKNOW (non-medical device) is a tool that uses a simple card test using a PC, tablet or smartphone device to perform tests evaluating psychomotor function, attention, learning and memory, and working memory. The results screen displays quantified indicators of brain performance, such as “memorization”, “cognition”, and “decision”, along with lifestyle advice. This digital tool allows users to self-assess independently and in a short time frame (approx. 15 minutes), enabling regular assessments in instances such as daily life and health checkups. It has been adopted by a number of medical and research institutions, municipalities, corporations and universities. It is expected that use of this tool to perform regular self-checks of brain health will become an opportunity to help the generation currently in their prime working years to gain a correct understanding of brain health and diseases, as well as to reconsider daily lifestyle, greater preventive measures, and consultation with doctors and other healthcare professionals.

For additional information, please visit https://nouknow.jp/. (Japanese only)
(List of partners: https://nouknow.jp/partner/

*The purpose of this tool is not to prevent or diagnose disease, but to raise awareness of brain health through regular checks.

Eisai will collaborate with local governments across Japan to create a community where citizens are aware of and check their brain health from the stage where they are healthy, aiming to realize a “Dementia-Inclusive Society” where everyone can live their lives how they would like.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
 
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
 
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
More Press release >>

Latest Press Release


More Latest Release >>